Neutralizing anti-CCL20 antibodies
US9809647B2 · kind B2 · utility
1Cited by
63References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 3, 2015 |
| Grant date | Nov 7, 2017 |
| Priority date | — |
| Expiry date | Aug 3, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/521
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.